Belantamab mafodotin-话题@MedSci

#Belantamab mafodotin#

0篇内容 | 565人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2237556, encodeId=d0c1223e556c4, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=68ca828e57' target=_blank style='color:#2F92EE;'>#GSK#</a> <a href='/topic/show?id=92801152391b' target=_blank style='color:#2F92EE;'>#Belantamab mafodotin#</a>, objectTitle=葛兰素史克靶向BCMA的ADC药物Blenrep治疗多发性骨髓瘤III期临床数据公布！无进展生存期36.6个月！, objectType=article, longId=851639, objectId=2a2d851639eb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20241101/5cc39cf274dd4f78920cd71bbf587ca5-oKOsR7vUwbnl.jpg, objectUrl=/article/show_article.do?id=2a2d851639eb, replyNumber=0, likeNumber=3, createdTime=2024-11-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=2a2d851639eb, moduleTitle=葛兰素史克靶向BCMA的ADC药物Blenrep治疗多发性骨髓瘤III期临床数据公布！无进展生存期36.6个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a2d851639eb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209083, encodeId=95ec220908395, content=<a href='/topic/show?id=793a101990ac' target=_blank style='color:#2F92EE;'>#骨髓瘤#</a> <a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a> <a href='/topic/show?id=92801152391b' target=_blank style='color:#2F92EE;'>#Belantamab mafodotin#</a>, objectTitle=【NEJM】Belantamab Mafodotin联合方案治疗RRMM的两项重磅研究, objectType=article, longId=829311, objectId=3205829311ee, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240609/1717906315398_5579292.jpg, objectUrl=/article/show_article.do?id=3205829311ee, replyNumber=0, likeNumber=93, createdTime=2024-06-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3205829311ee, moduleTitle=【NEJM】Belantamab Mafodotin联合方案治疗RRMM的两项重磅研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3205829311ee)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208547, encodeId=31be220854e95, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a> <a href='/topic/show?id=c0f04250423' target=_blank style='color:#2F92EE;'>#复发/难治性多发性骨髓瘤#</a> <a href='/topic/show?id=92801152391b' target=_blank style='color:#2F92EE;'>#Belantamab mafodotin#</a>, objectTitle=NEJM：Belantamab Mafodotin、硼替佐米和地塞米松治疗多发性骨髓瘤, objectType=article, longId=828958, objectId=22718289588b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240605/1717614823899_4754896.png, objectUrl=/article/show_article.do?id=22718289588b, replyNumber=0, likeNumber=128, createdTime=2024-06-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亚, moduleDTOList=[ModuleDTO(moduleId=22718289588b, moduleTitle=NEJM：Belantamab Mafodotin、硼替佐米和地塞米松治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22718289588b)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

多发性骨髓瘤复发/难治性多发性骨髓瘤 Belantamab mafodotin

2024-06-06发表于加利福尼亚

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #GSK# #Belantamab mafodotin#

葛兰素史克靶向BCMA的ADC药物Blenrep治疗多发性骨髓瘤III期临床数据公布！无进展生存期36.6个月！

2024-11-18发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#骨髓瘤# #治疗效果# #Belantamab mafodotin#

【NEJM】Belantamab Mafodotin联合方案治疗RRMM的两项重磅研究

2024-06-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#多发性骨髓瘤# #复发/难治性多发性骨髓瘤# #Belantamab mafodotin#

NEJM：Belantamab Mafodotin、硼替佐米和地塞米松治疗多发性骨髓瘤

2024-06-06发表于加利福尼亚

科室
- - 订阅+
  - 更多科室
工具
服务